Analysis of predicted coronary heart disease risk in England based on
Framingham study risk appraisal models published in 1991 and 2000
Kiran Nanchahal, lecturer in medical statisticsa, John R Duncan, statisticianb, Paul N Durrington, professor
of medicinec, Rodney T Jackson,
professor of epidemiologyd.
a Health Promotion Research Unit, Department of Public Health and
Policy, London School of Hygiene and Tropical Medicine, London WC1E 7HT, b GlaxoSmithKline,
New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, c Clinical
Research Division II, University Medical Unit, Manchester Royal Infirmary,
Manchester M13 9WL, d Faculty of Medical and Health Sciences,
University of Auckland, Grafton Mews, 52-54 Grafton Road, Auckland, New Zealand
In 2000 the UK government launched the national service framework for
coronary heart disease, setting national standards forimproving
prevention, diagnosis, and treatment. In agreement withrecent
recommendations on preventing coronary heart disease1and managing hypertension,2 this programme
includes use ofcoronary risk appraisal models from the Framingham
study publishedin 19913 to help
identify patients eligible for drug treatment.These models were
updated in 2000,4 incorporating further followup and additional risk factors. We compare the predicted risks
calculated using the two models and assess the implications for
preventing heart disease.
Number of participants and mean (SD) risk in
four year predicted risk categories based on coronary heart disease risk
appraisal models from the Framingham study published in 19913
and 20004
The health survey for England is an annual, nationwide, household based,
cross sectional survey of a representative sampleof the population.
We used the 1998 survey data for 5518 (62.3%of 8852) participants
aged 35-74 with complete information onfactors needed for assessment
of coronary disease risk, afterexclusion of 738 (7.7% of 9590)
participants reporting angina,heart attack, or stroke diagnosed by a
doctor.5 The 2000 modelsallow
calculation of risk over a period of four years,4
whereasthe 1991 models permit estimation of risk over 4-12 years.3We estimated the 10 year and four year probabilities of developingheart disease predicted using the 1991 equations and the four
year risk predicted using the 2000equations.
Summary statistics for four year coronary disease risk per 100 population
based on the 1991 and 2000 models within a rangeof risk categories
show that both models generally produce similardistributions
(table). Although substantial statistical agreementexists between
classification of participants into risk categoriesbased on the two
models, participants within each category basedon the 1991 models
were distributed across a wide range of riskcategories based on the
2000models.
Although population distributions of coronary risk calculated with the two
models are generally similar, a significant numberof people meeting
criteria for drug treatment on the basis ofthe 1991 models would not
meet the equivalent criteria on thebasis of the 2000 models. Current
UK guidelines generally recommendoffering drug treatment for
hypertension or hypercholesterolaemiato patients with a 10 year risk
15%. 12 We used a 5% riskof a coronary event
in four years as being equivalent to a 10year risk of 15%, rather
than 6% over four years, because riskincreases exponentially rather
than linearly with age. Had weused 6%, the discrepancy between the
1991 and 2000 models wouldhave been evengreater.
Our study confirms that risk of coronary disease in Britain is high. On the
basis of the 1991 risk appraisal models, approximately32% of men and
7% of women aged 35-74 in England are at
15% riskof developing
heart disease in the next 10 years. The 2000 modelsgive figures for
a four year risk 5% of 29% for
men and 6% forwomen. Although only 1-2% of men and women ineligible
for drugtreatment under current criteria would be eligible if the
2000models were used, 20% of men and 43% of women currently
recommendeddrug treatment would not be eligible if their four year
risk basedon the updated models was used. Sensitivity and
specificity forthe 1991 risk appraisal models would be 97.6% and
90.0% for menand 79.7% and 96.0% for women, considering the updated
modelsto provide the most up to date assessment of coronary diseaserisk for asymptomatic men and women. Although thresholds for drugtreatment are somewhat arbitrary and depend to a large degree
on the resources available, we recommend that these findings are
taken into account when guidelines for coronary heart disease
prevention are updated in accordance with emerging scientific
evidence for statin treatment and management of mildhypertension.
Acknowledgments
We thank J N Morris for comments on an earlier draft of the
manuscript.
Contributors: KN devised this study and drafted the manuscript of the paper,
JD undertook the statistical analyses, and all authors contributed to writing
the paper. KN will act as guarantor.
Footnotes
JD received a SmithKline Beecham scholarship while an MSc student at the
London School of Hygiene and Tropical Medicine whensome of this work
wasdone.
British Cardiac Society, British Hyperlipidaemia
Association, British Hypertension Society, British Diabetic Association.
Joint British recommendations on prevention of coronary heart disease in
clinical practice. Heart 1998; 80: S1-29.
Ramsay LE, Williams B, Johnston DG, MacGregor GA, Poston L,
Potter JF, et al. British Hypertension Society guidelines for hypertension
management 1999: summary. BMJ 1999; 319: 630-635[Full
Text].
Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated
coronary risk factor profile: a statement for health professionals.
Circulation 1991; 83: 356-362[Medline].
D'Agostino RB, Russell MW, Huse DM, Ellison C, Silbershatz
H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new
results from the Framingham study. Am Heart J 2000; 139: 272-281[Medline].
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
"What's the point of vaccination if it doesn't protect you from the unvaccinated?"
-- Sandy Gottstein
"Who gets to decide what the greater good is and how many will be sacrificed to it?"